Migd-061

| Indication | TAM (2026, $B) | Current Standard of Care | Competitive Edge of MIGD‑061 | |------------|----------------|--------------------------|-------------------------------| | | 45 | PD‑1/PD‑L1 mAbs (pembrolizumab, nivolumab) ± CTLA‑4 | First‑in‑class ISR modulator ; potential to convert “cold” tumours to “hot” via immune‑reprogramming. | | Amyotrophic Lateral Sclerosis (ALS) | 6 | Riluzole, edaravone (limited efficacy) | Oral, disease‑modifying mechanism distinct from excitotoxicity; Orphan designation may accelerate path to market. | | Flavivirus infections (Dengue, Zika) | 1.2 (episodic) | Supportive care | Host‑targeted antiviral with high barrier to resistance. |

To help you write a about it, could you clarify: migd-061